Diamedic Therapeutics (DMAC) Q1 2026: R&D Expenses Rise 40% as Remedy 2 Stroke Trial Surpasses 70% Enrollment
Diamedic Therapeutics advanced its clinical pipeline this quarter, with Remedy 2 stroke trial enrollment surpassing 70% and expanded efforts in preeclampsia and fetal growth restriction studies. R&D spending accelerated as the company prioritized multi-country site activations and regulatory workarounds, while management reiterated cash runway through 2027. The next two quarters will be pivotal as interim data readouts and regulatory feedback drive program momentum and investor visibility.
Summary
- Remedy 2 Enrollment Milestone: Over 70% of target stroke patients enrolled, with interim analysis expected by year-end.
- Preeclampsia Program Expansion: Multiple new cohorts and global trial sites set to launch as regulatory navigation continues.
- Cash Runway Emphasis: Management signals funding through 2027, aligning with key clinical milestones.
Business Overview
Diamedic Therapeutics is a clinical-stage biopharmaceutical company focused on developing DM-199, a recombinant human KLK1 protein, for vascular and pregnancy-related disorders. The company’s core revenue model relies on advancing DM-199 through late-stage clinical trials targeting preeclampsia, acute ischemic stroke, and fetal growth restriction, with the goal of eventual regulatory approval and commercial partnerships. Its major programs include the Remedy 2 global Phase 2/3 stroke trial and multi-cohort clinical studies in preeclampsia and fetal growth restriction, spanning North America, Europe, and South Africa.
Performance Analysis
Diamedic’s financial profile this quarter reflects the scale-up of its clinical pipeline. Cash and short-term investments declined to $51.3 million from $59.9 million at year-end, reflecting a net cash burn of $9.1 million, up from $7.1 million in the prior-year quarter. The company’s working capital position, now at $46.6 million, supports its stated plan to fund operations into 2027. R&D expenses rose sharply to $8 million, up 40% year-over-year, driven by Remedy 2’s global expansion, new site activations, and additional reproductive toxicity studies required by the FDA for the preeclampsia program. General and administrative costs remained flat at $2.5 million, signaling tight expense control outside of core development.
Operationally, Remedy 2 stroke trial enrollment surpassed 70% of target patients, with site activations now spanning the US, Canada, UK, and six additional European countries. The preeclampsia program advanced with near-completion of the late-onset extension cohort and preparations to launch two new cohorts (late and early-onset) plus a fetal growth restriction study. Regulatory hurdles persist in the US, where the FDA requested additional animal studies, but parallel progress in Canada and the UK mitigates timeline risk. Management expects R&D to moderately increase in coming quarters, driven by further trial expansion and enrollment acceleration.
- R&D Spend Acceleration: Remedy 2 trial and preeclampsia regulatory work drove a 40% YoY rise in R&D costs.
- Operational Breadth: 70 clinical sites activated globally, supporting multi-program patient recruitment.
- Cash Runway Alignment: Liquidity positioned to support all planned studies through 2027 milestones.
With multiple interim data readouts expected over the next 12 months, Diamedic’s financial and operational profile is increasingly synchronized with its clinical catalysts.
Executive Commentary
"We are pleased with the progress we've made so far in 2026 as we continue to advance DM-109 across both our preeclampsia and acute ischemic stroke programs. Most importantly for our shareholders, we're poised to deliver multiple clinical milestones between now and the end of 2027, all of which could provide significant validation of the value of DM-199."
Rick Pauls, President and Chief Executive Officer
"We anticipate that our current cash and investments will be sufficient to fund our planned clinical studies and operations through 2027. We expect that our R&D expenses will moderately increase in future periods relative to recent prior periods as we continue our remedy to trial and continue to advance our DM-199 clinical development program into PE."
Scott Kallen, Chief Financial Officer
Strategic Positioning
1. Remedy 2 Stroke Program: Global Scale and Data Inflection
Remedy 2, Diamedic’s flagship late-stage trial for acute ischemic stroke, is now enrolling across 70 sites in North America and Europe. With enrollment surpassing 70% of target, the company is positioned for an interim analysis by year-end 2026, which will drive a go/no-go decision and potential resampling for final study size. Positive interim data could validate both clinical effect and commercial potential, leveraging prior Remedy 1 results showing a 19% improvement in functional outcomes for moderate stroke patients.
2. Preeclampsia Program: Multi-Cohort and Regulatory Navigation
The preeclampsia pipeline is expanding with new late-onset and early-onset cohorts, plus a fetal growth restriction study. Diamedic is executing a parallel regulatory strategy: advancing in Canada and the UK while addressing FDA requirements for a new animal toxicology study in the US. This multi-track approach mitigates regional regulatory risk and accelerates patient accrual for future pivotal studies.
3. Capital Discipline and Cash Runway
Management’s explicit guidance on cash runway through 2027 is crucial for investor confidence, given the capital intensity of late-stage clinical development. The company is prioritizing R&D allocation to high-value inflection points, while keeping G&A flat, reflecting a disciplined approach to resource deployment.
4. Data-Driven Milestone Cadence
Diamedic is committed to providing interim updates as meaningful data emerges, especially from the preeclampsia and stroke programs. This transparency, combined with a cadence of cohort completions and regulatory submissions, aims to maintain investor engagement and support valuation as clinical risk is retired.
Key Considerations
This quarter’s operational progress is matched by a deliberate effort to de-risk timelines through geographic and regulatory diversification. Diamedic’s approach to trial design, site activation, and regulatory engagement is central to sustaining momentum and managing downside risk.
Key Considerations:
- Interim Data Readouts: Both Remedy 2 and preeclampsia programs will generate interim data in the next 6-12 months, directly impacting program prioritization and investor sentiment.
- Regulatory Uncertainty: FDA’s requirement for additional animal studies could delay US preeclampsia enrollment, but Canadian and UK progress offers a hedge.
- Cost Structure Management: R&D increases are expected to remain moderate, with CFO signaling no order-of-magnitude jumps, supporting cash runway claims.
- Site Activation and Enrollment Velocity: The ability to maintain or accelerate enrollment across 70+ sites is critical to timely data delivery and value inflection.
Risks
Diamedic faces classic late-stage biotech risks, including regulatory delays, clinical trial enrollment variability, and the binary nature of pivotal data readouts. FDA-mandated animal studies introduce timeline uncertainty for US preeclampsia trials, and geographic expansion, while mitigating some risk, adds operational complexity. Cash runway is sufficient for planned studies, but any material delay or negative data could require new capital or program reprioritization.
Forward Outlook
For Q2 and the remainder of 2026, Diamedic guided to:
- Completion of the late-onset preeclampsia extension cohort and data update this quarter.
- Initiation of Part 1B and Part 2 preeclampsia cohorts in summer 2026, with first fetal growth restriction patients enrolled this quarter.
- Remedy 2 interim analysis by year-end, with full enrollment targeted for Q1 2027.
For full-year 2026, management maintained guidance:
- Cash and investments sufficient to fund operations through 2027.
- Moderate sequential increases in R&D, with no material change in G&A.
Management highlighted several factors that will shape the year:
- FDA feedback on animal study design and timing for US preeclampsia trial initiation.
- Pace of enrollment and site activation in global stroke and preeclampsia programs.
Takeaways
Diamedic’s Q1 2026 results underscore a decisive shift into global late-stage execution, with clear data and regulatory milestones ahead.
- Remedy 2 and preeclampsia programs are the dual engines for value creation, with operational momentum and cash runway supporting near-term data catalysts.
- Regulatory navigation remains a gating factor, but parallel progress in Canada and the UK reduces the impact of potential US delays.
- Investors should closely watch interim data updates and FDA responses, as these will dictate both timeline and capital needs into 2027.
Conclusion
Diamedic Therapeutics is entering a pivotal period, with Remedy 2 stroke and preeclampsia programs approaching key data readouts and regulatory milestones. The company’s disciplined capital management and global trial execution provide a solid foundation, but investor focus should remain on clinical outcomes and regulatory clarity through the second half of 2026.
Industry Read-Through
Diamedic’s multi-country approach to clinical trial execution highlights a broader trend among small-cap biotechs: regulatory uncertainty in the US is increasingly prompting parallel development in Canada, the UK, and Europe to maintain momentum. Rising R&D spend and site activation complexity are common as companies chase diverse patient populations and de-risk timelines. The company’s willingness to provide interim updates and pursue adaptive trial designs reflects heightened investor demand for data visibility and milestone cadence. For peers in the stroke and maternal health space, the Remedy 2 and preeclampsia trial outcomes will serve as a bellwether for both regulatory strategy and commercial potential.